Titan Pharmaceuticals INC
Market Movers (8-K)
Titan Pharmaceuticals, Inc. completed its business combination with Black Titan Corporation, resulting in TTNP becoming a wholly-owned subsidiary and its shares converting to Black Titan Ordinary Shares.
Titan Pharmaceuticals, Inc. stockholders approved the proposed business combination with Black Titan Corporation and TalenTec Sdn. Bhd. at a special meeting.
8-K: Titan Pharmaceuticals Secures $600,000 Through Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals, Inc. has completed a private placement, raising $600,000 through the issuance of Series C Convertible Preferred Stock to Blue Harbour Asset Management L.L.C-FZ.
Capital raise
Titan Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of five directors, the issuance of over 20% of common stock for a private placement, and an amendment to its equity incentive plan.
Capital raise
Titan Pharmaceuticals, Inc. announced the filing of a Form F-4 registration statement with the SEC, including a preliminary proxy statement/prospectus, for its proposed reverse merger with TalenTec Sdn. Bhd. under the new holding company, Black Titan Corporation.
Titan Pharmaceuticals, Inc. has completed the conversion of Series AA and Series B Convertible Preferred Stock held by The Sire Group Ltd. and Blue Harbour Asset Management L.L.C-FZ into common stock, resulting in the issuance of 415,000 new common shares.
Capital raise
Quarterly Earnings (10-Q)
Titan Pharmaceuticals reported significantly reduced net losses and improved cash flow, while progressing towards a reverse merger with TalenTec and resolving Nasdaq listing compliance issues.
Better than expected
Capital raise
10-Q: Titan Pharmaceuticals Reports Q1 2025 Results, Focuses on Strategic Merger and Nasdaq Compliance
Titan Pharmaceuticals reported a net loss for Q1 2025, continues to pursue a merger with TalenTec, and addresses Nasdaq compliance concerns.
Worse than expected
Capital raise
Titan Pharmaceuticals reported its Q3 2024 financial results, highlighting a net loss and ongoing strategic transition, including a planned merger with TalenTec.
Worse than expected
Titan Pharmaceuticals reported its Q2 2024 results, highlighting a strategic shift towards product development and significant leadership changes.
Worse than expected
Capital raise
10-Q: Titan Pharmaceuticals Reports Q1 2024 Results, Navigates Leadership Changes and Strategic Shifts
Titan Pharmaceuticals reported a net loss of $1.1 million for Q1 2024, alongside leadership changes and ongoing strategic shifts following the sale of key assets.
Worse than expected
Capital raise
Annual Reports (10-K)
Titan Pharmaceuticals reports its financial results for the year ended December 31, 2024, highlighting a net loss and ongoing efforts to complete a merger with TalenTec Sdn. Bhd.
Worse than expected
Titan Pharmaceuticals reports a net loss of $5.6 million for 2023, transitioning to a product development company after selling its ProNeura assets.
Capital raise
Worse than expected
Insider Trading (Form 4)
Titan Pharmaceuticals director Avraham Ben-Tzvi reported the disposition of all his common stock and options following the merger with Black Titan Corporation.
Titan Pharmaceuticals, Inc. announced the filing of a Form F-4 registration statement with the SEC, containing a preliminary proxy statement/prospectus for its proposed reverse merger with TalenTec Sdn. Bhd. under the new holding company, Black Titan Corporation.
Titan Pharmaceuticals has entered into a merger agreement with KE Sdn. Bhd., a human capital management solutions provider, in a reverse merger transaction.
Worse than expected
Capital raise
Form 4: Titan Pharmaceuticals Insider Choong Choon Hau Converts $500,000 Promissory Note to Common Stock
Choong Choon Hau, a director and 10% owner of Titan Pharmaceuticals, converted $500,000 of a convertible promissory note into 54,132 shares of common stock on March 18, 2024.
Proxy Statements (Def-14A)
Titan Pharmaceuticals, Inc. files a supplement to its proxy statement, updating details on its business combination with Black Titan Corporation, including an increase in the Series A Preferred Shares PIPE financing to $6 million.
Worse than expected
Capital raise
Titan Pharmaceuticals, Inc. filed a supplement to its proxy statement, incorporating Black Titan Corporation's updates regarding a proposed business combination, including increased share capital and a new placement agent for future financing.
Capital raise
Titan Pharmaceuticals, Inc. has filed a definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.
DEFM14A: Titan Pharmaceuticals to Merge with Black Titan and TalenTec in Strategic Reverse Recapitalization
Titan Pharmaceuticals, Inc. (TTNP) is set to undergo a reverse merger with Black Titan Corporation (PubCo) and acquire Malaysia-based human capital management solutions provider TalenTec Sdn. Bhd., aiming to revitalize its business and list the combined entity on Nasdaq under the symbol BTTC.
Capital raise
DEFA14A: Titan Pharmaceuticals Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting
Titan Pharmaceuticals is soliciting proxies for its Annual Meeting of Stockholders to be held on June 16, 2025, covering director elections, plan amendments, stock issuance, auditor ratification, executive compensation approval, and say-on-pay frequency.
Capital raise
Titan Pharmaceuticals is holding its annual meeting on June 16, 2025, seeking stockholder approval for several key proposals, including a share issuance related to a private placement, an amendment to its equity incentive plan, and the ratification of its independent auditor.
Capital raise
Worse than expected